Integrated BioPharma, Inc. (PK:INBP)
Business Focus: Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 225 Long Ave Ste 15 HILLSIDE NJ 07205-2356 |
| Tel: | 1-888-3196962 |
| Website: | https://ir.ibiopharma.com |
| IR: | See website |
| Key People | ||
| Christina Kay Co-Chief Executive Officer, Director | Riva Sheppard Co-Chief Executive Officer, Director | Dina L. Masi Chief Financial Officer, Senior Vice President, Secretary |
| Business Overview |
| Integrated Biopharma Inc. is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements, and herbal products. The Company's business segments include Contract Manufacturing operated by Manhattan Drug Company, Inc. (MDC), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; and Other Nutraceutical Businesses, which includes the operations of AgroLabs, Inc. (AgroLabs), The Vitamin Factory (the Vitamin Factory), IHT Health Products, Inc. (IHT), MDC Warehousing and Distribution, Inc., and Chem International, Inc. AgroLabs distributes healthful nutritional products for sale through mass market, grocery and drug and vitamin retailers under the brands: Peaceful Sleep, and Wheatgrass and other products. IHT is a distributor of fine natural botanicals, including multi-minerals produced under a license agreement. Chem is a distributor of raw materials. |
| Financial Overview |
| For the six months ended 31 December 2023, Integrated BioPharma, Inc. revenues decreased 1% to $24.4M. Net loss increased from $90K to $441K. Revenues reflect Other Nutraceutical Businesses segment decrease of 30% to $934K, International segment decrease of 26% to $3.3M. Higher net loss reflects Unrealized loss on investment decrease from $27K (income) to $0K, Other income decrease from $7K (income) to $2K (expense). |
| Employees: | 141 as of Sep 15, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $5.77M as of Dec 31, 2023 |
| Annual revenue (TTM): | $50.52M as of Dec 31, 2023 |
| EBITDA (TTM): | -$0.05M as of Dec 31, 2023 |
| Net annual income (TTM): | -$0.39M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$0.33M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 30,099,610 as of Feb 12, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.